Halozyme Therapeutics Inc. | Mid-cap | Healthcare
$52.92
1.73%
| Halozyme Stock Comparison:
Halozyme vs VertexHalozyme vs RegeneronHalozyme vs Blueprint MedicinesHalozyme vs Roivant SciencesHalozyme vs Bio-TechneHalozyme vs S&P 500 | Market
Overview Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

Financial Overview

Latest Annual: 2024

Income Metrics

Revenue 1.0B
Gross Profit 855.9M 84.30%
Operating Income 551.5M 54.32%
Net Income 444.1M 43.74%
EPS (Diluted) $3.43

Balance Sheet Metrics

Total Assets 2.1B
Total Liabilities 1.7B
Shareholders Equity 363.8M
Debt to Equity 4.67

Cash Flow Metrics

Operating Cash Flow 436.1M
Free Cash Flow 468.4M

Revenue & Profitability Trend

Halozyme Income Statement From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Revenue 1.0B 829.3M 660.1M 443.3M 267.6M
Cost of Goods Sold 159.4M 192.4M 139.3M 81.4M 43.4M
Gross Profit 855.9M 636.9M 520.8M 361.9M 224.2M
Operating Expenses 233.4M 225.5M 210.1M 86.0M 80.0M
Operating Income 551.5M 337.6M 267.5M 275.9M 144.3M
Pre-tax Income 557.1M 348.3M 248.9M 248.5M 129.3M
Income Tax 113.0M 66.7M 46.8M -154.2M 217.0K
Net Income 444.1M 281.6M 202.1M 402.7M 129.1M
EPS (Diluted) $3.43 $2.10 $1.44 $2.74 $0.91

Income Statement Trend

Halozyme Balance Sheet From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Assets
Current Assets 1.1B 746.4M 739.0M 926.3M 554.8M
Non-Current Assets 978.1M 986.8M 1.1B 178.1M 25.2M
Total Assets 2.1B 1.7B 1.8B 1.1B 579.9M
Liabilities
Current Liabilities 139.1M 112.5M 130.8M 117.1M 421.4M
Non-Current Liabilities 1.6B 1.5B 1.5B 790.3M 7.5M
Total Liabilities 1.7B 1.6B 1.7B 907.5M 428.9M
Equity
Total Shareholders Equity 363.8M 83.8M 169.8M 197.0M 151.0M

Balance Sheet Composition

Halozyme Cash Flow Statement From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Operating Activities
Net Income 444.1M 281.6M 202.1M 402.7M 129.1M
Operating Cash Flow 436.1M 402.7M 221.7M 307.6M 93.5M
Investing Activities
Capital Expenditures -10.7M -15.3M -4.8M -1.5M -1.4M
Investing Cash Flow -262.7M -96.9M -487.0M -406.3M 78.4M
Financing Activities
Dividends Paid - - - - -
Financing Cash Flow -250.0M -415.9M 348.3M 65.3M -169.7M
Free Cash Flow 468.4M 373.3M 235.3M 298.0M 53.0M

Cash Flow Trend

Halozyme Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) 14.04
Forward P/E 10.91
Price to Book 13.49
Price to Sales 6.00
PEG Ratio 10.91

Profitability Ratios

Profit Margin 44.76%
Operating Margin 53.44%
Return on Equity 147.06%
Return on Assets 18.50%

Financial Health

Current Ratio 8.39
Debt to Equity 318.67
Beta 1.18

Per Share Data

EPS (TTM) $3.76
Book Value per Share $3.92
Revenue per Share $8.61

Peer Financial Comparison

Company Market Cap P/E Ratio P/B Ratio ROE Profit Margin Debt/Equity
halo 6.5B 14.04 13.49 147.06% 44.76% 318.67
Vertex 114.1B 32.82 6.92 -5.64% -8.91% 10.00
Regeneron 55.3B 13.02 1.84 15.96% 31.94% 9.20
Blueprint Medicines 8.3B -120.00 24.19 -47.71% -27.70% 208.50
Roivant Sciences 7.8B 1.95 1.71 -12.54% 96.86% 1.93
Bio-Techne 7.9B 60.87 3.92 6.53% 10.89% 20.99

Financial data is updated regularly. All figures are in the company's reporting currency.